Solid Biosciences Joins the Russell 3000® Index

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, announced it has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective July 1st, 2024.

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000^® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000^® Index or small-cap Russell 2000^® Index and the appropriate growth and value style indexes. FTSE Russell determines membership for its indexes primarily by objective, market-capitalization rankings, and style attributes.

“Our inclusion in the Russell 3000 Index is a reflection of our significant progress as we continue to execute across our pipeline initiatives,” said Bo Cumbo, President and CEO, of Solid Biosciences. “Joining this prestigious index is an important milestone for Solid as it brings our company enhanced exposure and broader visibility within the financial community.”

Read more about Solid Biosciences Joins the Russell 3000® Index.